logo
  

Voip-Pal.com Gets Offer To Monetize Technology

Voip-Pal.com Inc. (VPLM.PK) announced that a written offer has been received to monetize its telephony technology. Discussions conducted during the recent blackout period, which ended at the close of the market on July 3, 2014, resulted in a written offer to license and/or purchase Voip-pal's patent portfolio.

The company stated that negotiations with respect to this offer and discussions with other prospective purchasers, licensees and partners continue to be conducted in order to assure the best possible outcome for Voip-Pal shareholders.

However, Voip-Pal said it cannot disclose additional details at this time, due to non-disclosure/confidentiality agreements.

Thomas Sawyer, Chairman and CEO of Voip-Pal said,"While management and the Board had hoped to have a conclusive agreement in place prior to the end of the blackout, we are pleased with the meaningful progress toward that end and we remain very positive for the outcome of the company and returns for the shareholders. Our efforts will continue until the Board is able to negotiate a stronger proposal that it can recommend for shareholder approval."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT